Pharm House - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 394,799 | 380,737 | 555,494 | 758,718 | 1,063,396 | 1,663,572 | 2,203,946 | 2,344,838 |
| Profit before tax | - | - | - | - | - | - | 635,235 | 633,506 |
| Net profit | 65,835 | 61,718 | 147,159 | 155,680 | 248,302 | 419,560 | 539,645 | 532,649 |
| Equity | 123,727 | 114,857 | 226,721 | 347,108 | 489,528 | 589,658 | 894,008 | 1,073,716 |
| Liabilities | 38,954 | 53,771 | 63,166 | 137,218 | 244,502 | 172,857 | 513,615 | 371,700 |
| Non-current assets | 1,346 | 4,057 | 28,982 | 59,265 | 78,582 | 69,034 | 198,056 | 198,936 |
| Current assets | 161,335 | 164,175 | 259,266 | 422,896 | 649,989 | 689,824 | 1,199,435 | 1,236,494 |
| Total assets | 162,681 | 168,232 | 288,248 | 482,161 | 728,571 | 758,858 | 1,397,491 | 1,435,430 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 169,823 | 231,105 | 266,197 |
| Social insurance contributions | - | - | - | - | - | 22,701 | 27,320 | 32,412 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +71.6% | -3.6% | +45.9% | +36.6% | +40.2% | +56.4% | +32.5% | +6.4% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 40.5% | 36.7% | 51.1% | 32.3% | 34.1% | 55.3% | 38.6% | 37.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 53.2% | 53.7% | 64.9% | 44.9% | 50.7% | 71.2% | 60.4% | 49.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 16.7% | 16.2% | 26.5% | 20.5% | 23.3% | 25.2% | 24.5% | 22.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | 28.8% | 27.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.5 | 0.3 | 0.4 | 0.5 | 0.3 | 0.6 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 100,799 | 91,376 | 111,099 | 146,848 | 209,194 | 307,119 | 367,324 | 390,806 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Pharm House - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2022-08-23 | 2022-08-23 | 38.91 |
Pharm House - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-09-28 | 2025-09-29 | 6055.72 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Pharm House, UAB (company code 304114456) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated EUR 2.34 million in revenue, up 6.4% year on year and 41.0% over two years. Net profit in 2025 was EUR 532.6 thousand, slightly below the EUR 539.6 thousand recorded in 2024, while the profit margin remained solid at 22.7%. The three-year trend shows steady expansion: revenue rose from EUR 1.66 million in 2023 to EUR 2.20 million in 2024 and EUR 2.34 million in 2025, while net profit increased from EUR 419.6 thousand to EUR 539.6 thousand and then stayed broadly stable in 2025. At the end of 2025, total assets were EUR 1.44 million, equity EUR 1.07 million, and liabilities EUR 371.7 thousand, indicating a strong capital structure with an equity ratio of 74.8% and debt-to-equity of 0.35. Operational efficiency was also strong, with asset turnover of 1.63x and revenue per employee of EUR 390.8 thousand.